
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.